Has Sheera Siegel, MD received payments from drug or device companies?

Yes. Drug and device makers reported $12,380 in general payments to Sheera Siegel, MD across 865 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Sheera Siegel, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Sheera Siegel, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Sheera Siegel, MD

Endocrinology, Diabetes & Metabolism · Florham Park, NJNPI 1285686626

Payments from drug & device makers

$12,380in general payments, 2019–2025

Across 865 payments — averaging $14.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Novo Nordisk$3K
Lilly USA, LLC$1K
Amgen$844
Abbott$768
Boehringer Ingelheim$621
AbbVie$453
plus $6K from 54 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Novo Nordisk	223	$2,557
Lilly USA, LLC	82	$1,158
Amgen	63	$844
Abbott	30	$768
Boehringer Ingelheim	40	$621
AbbVie	44	$453
Sanofi-aventis U.S. LLC	29	$429
Dexcom, Inc.	19	$392
Amneal Pharmaceuticals LLC	24	$365
AstraZeneca(2 entities)	22	$328
Pfizer	23	$327
IBSA Pharma Inc.	21	$289
Merck	20	$282
Insulet Corporation	21	$275
Bayer	13	$247
Vivus LLC	17	$246
Xeris Pharmaceuticals, Inc.	15	$234
Medtronic(2 entities)	11	$180
Antares Pharma, Inc.	12	$161
Mannkind Corporation	8	$158
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	8	$121
Verity Pharmaceuticals Inc.	7	$115
Ipsen Biopharmaceuticals, Inc	6	$102
Corcept Therapeutics	6	$101
Tandem Diabetes Care, Inc.	5	$99
Radius Health, Inc.	6	$93
Ascendis Pharma Endocrinology Inc	5	$86
Recordati_rare_diseases_inc.	5	$81
Tolmar, Inc.	5	$78
Madrigal Pharmaceuticals	3	$77
Currax Pharmaceuticals LLC	5	$74
Johnson & Johnson(2 entities)	5	$68
Ascensia Diabetes Care US Inc.	2	$64
Kowa Pharmaceuticals America, Inc.	4	$57
Ultragenyx Pharmaceutical Inc.	4	$56
Eisai Inc.	4	$55
Embecta Corp.	4	$54
Neurocrine Biosciences, Inc.	3	$51
Novartis	2	$44
Arbor Pharmaceuticals, Inc.	3	$44
Amphastar Pharmaceuticals, Inc.	3	$42
Bausch Health US, LLC	2	$38
BETA Bionics, Inc.	2	$35
Averitas Pharma Inc.	2	$33
Astellas Pharma US Inc	2	$33
Idorsia Pharmaceuticals US Inc	2	$31
Takeda Pharmaceuticals U.S.A., Inc.	2	$29
Azurity Pharmaceuticals, Inc.	2	$29
BD	2	$29
Acerus Pharmaceuticals Corporation	2	$28
Amryt Pharma Holdings Ltd	2	$28
GSK	2	$27
Zealand Pharma US, Inc.	2	$26
Chiesi USA, Inc.	1	$24
Sequel Med Tech, LLC	1	$18
Cequr Corporation	1	$16
Clarus Therapeutics Inc.	1	$15
Esperion Therapeutics, Inc.	1	$14
Biohaven Pharmaceuticals, Inc.	1	$14
Shire North American Group Inc	1	$14

How this compares

$12,380 in reported general payments places this provider in the 80th percentile of 367 endocrinology, diabetes & metabolism providers in New Jersey.

See all endocrinology, diabetes & metabolism providers in New Jersey →

Medicare billing

Part B allowed, 2024

$212,172

Medicare patients

660

Services billed

2,053

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Florham Park

Anna KissinFlorham Park$14K
Barry GertzRahway$903K
Nawras MakhsidaRandolph$882K
Marc SandbergFlemington$567K
Joanne WaldstreicherNew Brunswick$441K
Gregory BaroneCherry Hill$433K
Taher ModarressiPennington$414K
Navtika DesaiHillsborough$408K
Atara SchultzTeaneck$357K
Anthony CannonTurnersville$296K

See the full list for New Jersey →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →